CXBS — Corix Bioscience Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
Annual income statement for Corix Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2012 January 31st | 2013 January 31st | 2014 January 31st | 2015 January 31st | 2016 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0.694 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.076 | 1.7 | 1.72 | 0.054 | 4.66 |
| Operating Profit | -0.076 | -1.7 | -1.72 | -0.054 | -3.97 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.076 | -1.7 | -1.72 | -0.057 | -4.43 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.076 | -1.7 | -1.72 | -0.057 | -4.43 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.076 | -1.7 | -1.72 | -0.057 | -4.43 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -0.076 | -1.7 | -1.72 | -0.057 | -4.43 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1,016 | -20,580 | -90 | -0.367 | -0.497 |
| Dividends per Share |